Issues in hypertriglyceridemic pancreatitis: An update

Journal of Clinical Gastroenterology

Volumn 48, Issue 3, 2014, Pages 195-203

  Scherer, John ^a   Singh, Vijay P ^a   Pitchumoni, C S ^b   Yadav, Dhiraj ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b SAINT PETER S UNIVERSITY HOSPITAL   (United States)

Author keywords

Hyperlipidemia; Hypertriglyceridemia; Pancreatitis

Indexed keywords

ACUTE DISEASE; BIOLOGICAL MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERTRIGLYCERIDEMIA; PANCREATITIS; RECURRENCE; RISK FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES; UP-REGULATION;

EID: 84894077068     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/01.mcg.0000436438.60145.5a     Document Type: Review

References (82)

1. Yadav D, Pitchumoni CS. Issues in hyperlipidemic pancreatitis. J Clin Gastroenterol. 2003;36:54-62.
2. Dominguez-Munoz JE, Malfertheiner P, Ditschuneit HH, et al. Hyperlipidemia in acute pancreatitis. Relationship with etiology, onset, and severity of the disease. Int J Pancreatol. 1991;10:261-267.
3. Balachandra S, Virlos IT, King NK, et al. Hyperlipidaemia and outcome in acute pancreatitis. Int J Clin Pract. 2006;60:156-159.
4. Fortson MR, Freedman SN, Webster PD III. Clinical assessment of hyperlipidemic pancreatitis. Am J Gastroenterol. 1995;90:2134-2139.
5. Saligram S, Lo D, Saul M, et al. Analyses of hospital administrative data that use diagnosis codes overestimate the cases of acute pancreatitis. Clin Gastroenterol Hepatol. 2012;10:805-811, e1.
6. Berglund L, Brunzell JD, Goldberg AC, et al. Evaluation and treatment of hypertriglyceridemia: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97: 2969-2989.
7. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106:3143-3421.
8. Christian JB, Bourgeois N, Snipes R, et al. Prevalence of severe (500 to 2000 mg/dL) hypertriglyceridemia in United States adults. Am J Cardiol. 2011;107:891-897.
9. Lindkvist B, Appelros S, Regner S, et al. A prospective cohort study on risk of acute pancreatitis related to serum triglycerides, cholesterol and fasting glucose. Pancreatology. 2012;12:317-324.
10. Bessembinders K, Wielders J, van de Wiel A. Severe hypertriglyceridemia influenced by alcohol (SHIBA). Alcohol Alcohol. 2011;46:113-116.
11. Lloret Linares C, Pelletier AL, Czernichow S, et al. Acute pancreatitis in a cohort of 129 patients referred for severe hypertriglyceridemia. Pancreas. 2008;37:13-22.
12. Sandhu S, Al-Sarraf A, Taraboanta C, et al. Incidence of pancreatitis, secondary causes, and treatment of patients referred to a specialty lipid clinic with severe hypertriglyceridemia: A retrospective cohort study. Lipids Health Dis. 2011;10:157.
13. Yadav D, Eigenbrodt ML, Briggs MJ, et al. Pancreatitis: Prevalence and risk factors among male veterans in a detoxification program. Pancreas. 2007;34:390-398.
14. Lambert JE, Parks EJ. Postprandial metabolism of meal triglyceride in humans. Biochim Biophys Acta. 2012;1821: 721-726.
15. Rader DJ. Lipid Disorders. In: Topol E, ed. Textbook of cardiovascular medicine. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2007.
16. Nair S, Yadav D, Pitchumoni CS. Association of diabetic ketoacidosis and acute pancreatitis: Observations in 100 consecutive episodes of DKA. Am J Gastroenterol. 2000;95:2795-2800.
17. Subramanian S, Chait A. Hypertriglyceridemia secondary to obesity and diabetes. Biochim Biophys Acta. 2012;1821: 819-825.
18. Girman CJ, Kou TD, Cai B, et al. Patients with type 2 diabetes mellitus have higher risk for acute pancreatitis compared with those without diabetes. Diabetes Obes Metab. 2010;12: 766-771.
19. Noel RA, Braun DK, Patterson RE, et al. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: A retrospective cohort study. Diabetes Care. 2009;32:834-838.
20. Lai SW, Muo CH, Liao KF, et al. Risk of acute pancreatitis in type 2 diabetes and risk reduction on anti-diabetic drugs: A population-based cohort study in Taiwan. Am J Gastroenterol. 2011;106:1697-1704.
21. Van de Wiel A. The effect of alcohol on postprandial and fasting triglycerides. Int J Vasc Med. 2012;2012:862504.
22. Goldenberg NM, Wang P, Glueck CJ. An observational study of severe hypertriglyceridemia, hypertriglyceridemic acute pancreatitis, and failure of triglyceride-lowering therapy when estrogens are given to women with and without familial hypertriglyceridemia. Clin Chim Acta. 2003;332:11-19.
23. Geng Y, Li W, Sun L, et al. Severe acute pancreatitis during pregnancy: Eleven years experience from a surgical intensive care unit. Dig Dis Sci. 2011;56:3672-3677.
24. Goodman MP. Are all estrogens created equal? A review of oral vs. transdermal therapy. J Womens Health (Larchmt).2012;21:161-169.
25. Arbel Y, Weinstein D, Yogev R, et al. Acute pancreatitis following clomiphene citrate treatment: Case report and review of the literature. Int J Surg. 2008;6:483-484.
26. Chen JL, Spinowitz N, Karwa M. Hypertriglyceridemia, acute pancreatitis, and diabetic ketoacidosis possibly associated with mirtazapine therapy: A case report. Pharmacotherapy. 2003; 23:940-944.
27. Devlin JW, Lau AK, Tanios MA. Propofol-Associated hypertriglyceridemia and pancreatitis in the intensive care unit: An analysis of frequency and risk factors. Pharmacotherapy. 2005;25:1348-1352.
28. Durrington PN, Cairns SA. Acute-pancreatitis: A complication of beta-blockade. Br Med J (Clin Res Ed). 1982;284:1016.
29. Gerstner T, Busing D, Bell N, et al. Valproic acid-induced pancreatitis: 16 new cases and a review of the literature. J Gastroenterol. 2007;42:39-48.
30. McCarter TL, Chen YK. Marked hyperlipidemia and pancreatitis associated with isotretinoin therapy. Am J Gastroenterol. 1992;87:1855-1858.
31. Riedel DJ, Gebo KA, Moore RD, et al. A ten-year analysis of the incidence and risk factors for acute pancreatitis requiring hospitalization in an urban HIV clinical cohort. AIDS Patient Care STDS. 2008;22:113-121.
32. Sakhri J, Ben Salem C, Harbi H, et al. Severe acute pancreatitis due to tamoxifen-induced hypertriglyceridemia with positive rechallenge. JOP. 2010;11:382-384.
33. Vivatrat N, Barshop BA, Jones KL. Severe hypertriglyceridemia and recurrent pancreatitis in a girl with type Ia glycogen storage disease and type III hyperlipoproteinemia. Am J Med Genet A. 2009;149A:2557-2559.
34. Garg A. Clinical review#: Lipodystrophies: Genetic and acquired body fat disorders. J Clin Endocrinol Metab. 2011;96:3313-3325.
35. Lesser PB, Warshaw AL. Diagnosis of pancreatitis masked by hyperlipemia. Ann Intern Med. 1975;82:795-798.
36. Warshaw AL, Bellini CA, Lesser PB. Inhibition of serum and urine amylase activity in pancreatitis with hyperlipemia. Ann Surg. 1975;182:72-75.
37. Banks PA, Freeman ML. Practice guidelines in acute pancreatitis. Am J Gastroenterol. 2006;101:2379-2400.
38. Forsmark CE, Baillie J. AGA institute technical review on acute pancreatitis. Gastroenterology. 2007;132:2022-2044.
39. Christophersen B, Nordstoga K, Shen Y, et al. Lipoprotein lipase deficiency with pancreatitis in mink: Biochemical characterization and pathology. J Lipid Res. 1997;38: 837-846.
40. Nordstoga K, Christophersen B, Ytrehus B, et al. Pancreatitis associated with hyperlipoproteinaemia type I in mink (Mustela vison): Earliest detectable changes occur in mitochondria of exocrine cells. J Comp Pathol. 2006;134:320-328.
41. Nordstoga K, Sorby R, Olivecrona G, et al. Pancreatitis in hyperlipemic Mink (Mustela vison). Vet Pathol. 2012;49:557-561.
42. Wang Y, Sternfeld L, Yang F, et al. Enhanced susceptibility to pancreatitis in severe hypertriglyceridaemic lipoprotein lipasedeficient mice and agonist-like function of pancreatic lipase in pancreatic cells. Gut. 2009;58:422-430.
43. Wang YJ, Sun JB, Li F, et al. Hyperlipidemia intensifies ceruleininduced acute pancreatitis associated with activation of protein kinase C in rats. World J Gastroenterol. 2006;12:2908-2913.
44. Yang F, Wang Y, Sternfeld L, et al. The role of free fatty acids, pancreatic lipase and Ca+ signalling in injury of isolated acinar cells and pancreatitis model in lipoprotein lipasedeficient mice. Acta Physiol (Oxf). 2009;195:13-28.
45. Navina S, Acharya C, DeLany JP, et al. Lipotoxicity causes multisystem organ failure and exacerbates acute pancreatitis in obesity. Sci Transl Med. 2011;3:107ra110.
46. Savonen R, Nordstoga K, Christophersen B, et al. Chylomicron metabolism in an animal model for hyperlipoproteinemia type I. J Lipid Res. 1999;40:1336-1346.
47. Lowe ME. The triglyceride lipases of the pancreas. J Lipid Res. 2002;43:2007-2016.
48. Singh VP, Saluja AK, Bhagat L, et al. Serine protease inhibitor causes F-Actin redistribution and inhibition of calciummediated secretion in pancreatic acini. Gastroenterology. 2001;120:1818-1827.
49. Anderson F, Thomson SR, Clarke DL, et al. Dyslipidaemic pancreatitis clinical assessment and analysis of disease severity and outcomes. Pancreatology. 2009;9:252-257.
50. Deng LH, Xue P, Xia Q, et al. Effect of admission hypertriglyceridemia on the episodes of severe acute pancreatitis. World J Gastroenterol. 2008;14:4558-4561.
51. Athyros VG, Giouleme OI, Nikolaidis NL, et al. Long-Term follow-up of patients with acute hypertriglyceridemia-induced pancreatitis. J Clin Gastroenterol. 2002;34:472-475.
52. Hacken JB, Moccia RM. Calcific pancreatitis in a patient with type 5 hyperlipoproteinemia. Gastrointest Radiol. 1979;4:143-146.
53. Krauss RM, Levy AG. Subclinical chronic pancreatitis in type I hyperlipoproteinemia. Am J Med. 1977;62:144-149.
54. Hoste P, Lentini F, Rottiers R. Chronic relapsing pancreatitis in twin-brothers with type V hyperlipoproteinemia. Acta Clin Belg. 1978;33:313-322.
55. Truninger K, Schmid PA, Hoffmann MM, et al. Recurrent acute and chronic pancreatitis in two brothers with familial chylomicronemia syndrome. Pancreas. 2006;32:215-219.
56. Chang YT, Chang MC, Su TC, et al. Association of cystic fibrosis transmembrane conductance regulator (CFTR) mutation/ variant/haplotype and tumor necrosis factor (TNF) promoter polymorphism in hyperlipidemic pancreatitis. Clin Chem. 2008;54:131-138.
57. O'Keefe SJ. A guide to enteral access procedures and enteral nutrition. Nat Rev Gastroenterol Hepatol. 2009;6:207-215.
58. Yi F, Ge L, Zhao J, et al. Meta-Analysis: Total parenteral nutrition versus total enteral nutrition in predicted severe acute pancreatitis. Intern Med. 2012;51:523-530.
59. Al-Humoud H, Alhumoud E, Al-Hilali N. Therapeutic plasma exchange for acute hyperlipidemic pancreatitis: A case series. Ther Apher Dial. 2008;12:202-204.
60. Chen JH, Yeh JH, Lai HW, et al. Therapeutic plasma exchange in patients with hyperlipidemic pancreatitis. World J Gastroenterol. 2004;10:2272-2274.
61. Gubensek J, Buturovic-Ponikvar J, Marn-Pernat A, et al. Treatment of hyperlipidemic acute pancreatitis with plasma exchange: A single-center experience. Ther Apher Dial. 2009;13:314-317.
62. Kyriakidis AV, Karydakis P, Neofytou N, et al. Plasmapheresis in the management of acute severe hyperlipidemic pancreatitis: Report of 5 cases. Pancreatology. 2005;5:201-204.
63. Yeh JH, Chen JH, Chiu HC. Plasmapheresis for hyperlipidemic pancreatitis. J Clin Apher. 2003;18:181-185.
64. Kohli RS, Bleibel W, Shetty A, et al. Plasmapheresis in the treatment of hypertriglyceridemic pancreatitis with ARDS. Dig Dis Sci. 2006;51:2287-2291.
65. Dettelbach MA, Deftos LJ, Stewart AF. Intraperitoneal free fatty acids induce severe hypocalcemia in rats: A model for the hypocalcemia of pancreatitis. J Bone Miner Res. 1990;5:1249-1255.
66. Domschke S, Malfertheiner P, Uhl W, et al. Free fatty acids in serum of patients with acute necrotizing or edematous pancreatitis. Int J Pancreatol. 1993;13:105-110.
67. Szczepiorkowski ZM, Winters JL, Bandarenko N, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher. 2010;25:83-177.
68. Cole RP. Heparin treatment for severe hypertriglyceridemia in diabetic ketoacidosis. Arch Intern Med. 2009;169:1439-1441.
69. Henderson SR, Maitland R, Mustafa OG, et al. Severe hypertriglyceridaemia in Type 2 diabetes mellitus: Beneficial effect of continuous insulin infusion. QJM. 2013;106:355-359.
70. Alagozlu H, Cindoruk M, Karakan T, et al. Heparin and insulin in the treatment of hypertriglyceridemia-induced severe acute pancreatitis. Dig Dis Sci. 2006;51:931-933.
71. Monga A, Arora A, Makkar RP, et al. Hypertriglyceridemiainduced acute pancreatitis-Treatment with heparin and insulin. Indian J Gastroenterol. 2003;22:102-103.
72. Twilla JD, Mancell J. Hypertriglyceridemia-induced acute pancreatitis treated with insulin and heparin. Am J Health Syst Pharm. 2012;69:213-216.
73. Nasstrom B, Olivecrona G, Olivecrona T, et al. Lipoprotein lipase during continuous heparin infusion: Tissue stores become partially depleted. J Lab Clin Med. 2001;138:206-213.
74. Weintraub M, Rassin T, Eisenberg S, et al. Continuous intravenous heparin administration in humans causes a decrease in serum lipolytic activity and accumulation of chylomicrons in circulation. J Lipid Res. 1994;35:229-238.
75. Christian JB, Arondekar B, Buysman EK, et al. Clinical and economic benefits observed when follow-up triglyceride levels are less than 500 mg/dL in patients with severe hypertriglyceridemia. J Clin Lipidol. 2012;6:450-461.
76. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001; 285:2486-2497.
77. Jacobson TA. Myopathy with statin-fibrate combination therapy: Clinical considerations. Nat Rev Endocrinol. 2009;5:507-518.
78. Schima SM, Maciejewski SR, Hilleman DE, et al. Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: Role of delayed-release fenofibric acid. Expert Opin Pharmacother. 2010;11:731-738.
79. Hooper L, Thompson RL, Harrison RA, et al. Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: Systematic review. BMJ. 2006;332:752-760.
80. Gaudet D, Methot J, Dery S, et al. Efficacy and long-Term safety of alipogene tiparvovec (AAV1-LPL(S447X)) gene therapy for lipoprotein lipase deficiency: An open-label trial. Gene Ther. 2013;20:361-369.
81. Stefanutti C, Di Giacomo S, Vivenzio A, et al. Therapeutic plasma exchange in patients with severe hypertriglyceridemia: A multicenter study. Artif Organs. 2009;33:1096-1102.
82. Schaap-Fogler M, Schurr D, Schaap T, et al. Long-Term plasma exchange for severe refractory hypertriglyceridemia: A decade of experience demonstrates safety and efficacy. J Clin Apher. 2009;24:254-258.